MX2016014299A - Metodo de tratamiento de linfoma no hodgkiniano resistente, meduloblastoma, y/o cancer de pulmon de celulas no pequeñas positivas a alk utilizando compuestos de tienotriazolodiazepina. - Google Patents
Metodo de tratamiento de linfoma no hodgkiniano resistente, meduloblastoma, y/o cancer de pulmon de celulas no pequeñas positivas a alk utilizando compuestos de tienotriazolodiazepina.Info
- Publication number
- MX2016014299A MX2016014299A MX2016014299A MX2016014299A MX2016014299A MX 2016014299 A MX2016014299 A MX 2016014299A MX 2016014299 A MX2016014299 A MX 2016014299A MX 2016014299 A MX2016014299 A MX 2016014299A MX 2016014299 A MX2016014299 A MX 2016014299A
- Authority
- MX
- Mexico
- Prior art keywords
- carbon number
- medulloblastoma
- alk
- halogen atom
- lung cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un método de tratamiento de linfoma no hodgkiniano resistente, meduloblastoma, y/o cáncer de pulmón de células no pequeñas positivas a ALK en un mamífero mediante la administración de una dispersión sólida que comprende un compuesto de tienotriazolodiazepina amorfo de la Fórmula (1) en donde R1 es alquilo que tiene un número de carbonos de 1 a 4, R2 es un átomo de hidrógeno; un átomo de halógeno; o alquilo que tiene un número de carbonos de 1 a 4 opcionalmente sustituidos por un átomo de halógeno o un grupo hidroxilo, R3 es un átomo de halógeno; fenilo opcionalmente sustituido por un átomo de halógeno, alquilo que tiene un número de carbonos de 1 a 4, alcoxí que tiene un número de carbonos de 1 a 4 o ciano; -NR 5 -{CH 2)m-,- R6 en donde R5 es un átomo de hidrógeno o alquilo que tiene un número de carbonos de 1 a 4, m es un número entero de 0 a 4, y R6 es fenilo o piridilo opcionalmente sustituido por un átomo de halógeno.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461987813P | 2014-05-02 | 2014-05-02 | |
US201461990469P | 2014-05-08 | 2014-05-08 | |
US201461990459P | 2014-05-08 | 2014-05-08 | |
PCT/US2015/028798 WO2015168555A1 (en) | 2014-05-02 | 2015-05-01 | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016014299A true MX2016014299A (es) | 2017-01-27 |
Family
ID=54359380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016014299A MX2016014299A (es) | 2014-05-02 | 2015-05-01 | Metodo de tratamiento de linfoma no hodgkiniano resistente, meduloblastoma, y/o cancer de pulmon de celulas no pequeñas positivas a alk utilizando compuestos de tienotriazolodiazepina. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20170095484A1 (es) |
EP (1) | EP3137086A4 (es) |
JP (1) | JP2017514907A (es) |
KR (1) | KR20170002550A (es) |
CN (1) | CN106687117A (es) |
AU (1) | AU2015252940A1 (es) |
CA (1) | CA2947593A1 (es) |
MX (1) | MX2016014299A (es) |
RU (1) | RU2016146102A (es) |
WO (1) | WO2015168555A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014143768A1 (en) | 2013-03-15 | 2014-09-18 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
CA2917319A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
BR112016024626B1 (pt) | 2014-04-23 | 2023-03-21 | Incyte Holdings Corporation | Compostos 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7 (6h)-onas, uso dos mesmos, composição farmacêutica que os compreende e método de inibição de uma proteína bet |
WO2016026912A1 (en) * | 2014-08-19 | 2016-02-25 | Oncoethix Gmbh | Methods of treating lymphoma using thienotriazolodiazepine compounds |
EP3194406B8 (en) | 2014-09-15 | 2021-03-31 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
US10683305B2 (en) | 2015-04-27 | 2020-06-16 | Concert Pharmaceuticals, Inc. | Deuterated OTX-015 |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
PE20190623A1 (es) | 2016-06-20 | 2019-04-26 | Incyte Corp | Formas solidas cristalinas de un inhibidor de bet |
HRP20220309T1 (hr) * | 2017-06-30 | 2022-05-13 | Acrotech Biopharma Llc | Nove oralne formulacije belinostata |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2412776C (en) * | 2000-06-16 | 2011-03-15 | Mitsubishi Pharma Corporation | Compositions controlling release ph range and/or speed |
KR101600634B1 (ko) * | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
SI2902030T1 (sl) * | 2010-05-14 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Tienotriazolodiazepinske spojine za zdravljenje neoplazije |
IN2014DN11269A (es) * | 2012-06-25 | 2015-10-09 | Oncoethix Sa | |
MX2015003771A (es) * | 2012-09-28 | 2016-03-04 | Oncoethix Gmbh | Formulacion farmaceutica que contiene compuestos de tienotriazolodiazepina. |
WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
JP2016538307A (ja) * | 2013-11-27 | 2016-12-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤を使用する非小細胞肺癌の治療方法 |
US9757385B2 (en) * | 2013-11-27 | 2017-09-12 | Merck Sharp & Dohme Corp. | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
-
2015
- 2015-05-01 KR KR1020167033941A patent/KR20170002550A/ko unknown
- 2015-05-01 RU RU2016146102A patent/RU2016146102A/ru not_active Application Discontinuation
- 2015-05-01 EP EP15786309.3A patent/EP3137086A4/en not_active Withdrawn
- 2015-05-01 US US15/308,548 patent/US20170095484A1/en not_active Abandoned
- 2015-05-01 CN CN201580036829.XA patent/CN106687117A/zh active Pending
- 2015-05-01 WO PCT/US2015/028798 patent/WO2015168555A1/en active Application Filing
- 2015-05-01 AU AU2015252940A patent/AU2015252940A1/en not_active Abandoned
- 2015-05-01 CA CA2947593A patent/CA2947593A1/en not_active Abandoned
- 2015-05-01 MX MX2016014299A patent/MX2016014299A/es unknown
- 2015-05-01 JP JP2017510449A patent/JP2017514907A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20170002550A (ko) | 2017-01-06 |
CA2947593A1 (en) | 2015-11-05 |
US20170095484A1 (en) | 2017-04-06 |
JP2017514907A (ja) | 2017-06-08 |
CN106687117A (zh) | 2017-05-17 |
RU2016146102A (ru) | 2018-06-05 |
WO2015168555A1 (en) | 2015-11-05 |
EP3137086A1 (en) | 2017-03-08 |
RU2016146102A3 (es) | 2018-12-17 |
EP3137086A4 (en) | 2017-12-27 |
AU2015252940A1 (en) | 2016-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016014299A (es) | Metodo de tratamiento de linfoma no hodgkiniano resistente, meduloblastoma, y/o cancer de pulmon de celulas no pequeñas positivas a alk utilizando compuestos de tienotriazolodiazepina. | |
MX2016014301A (es) | Metodo para tratar leucemia mieloide aguda y/o leucemia linfoblastica aguda usando compuestos de tienotriazolodiazepina. | |
EA033294B1 (ru) | Пиридазиноновые гербициды | |
MX358376B (es) | Nuevos derivados dihidroquinolina-2-ona. | |
PH12016500148A1 (en) | Plant disease control composition and its use | |
NZ748260A (en) | Substituted pyrimidine bmi-1 inhibitors | |
MX2014002208A (es) | Inhibidores de serina/treonina quinasa. | |
MX2013003960A (es) | Estabilizadores de luz de amina estericamente impedida con funcionalizacion mixta. | |
MX2015015786A (es) | Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas. | |
PH12016500643B1 (en) | NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c'] DIPYRROL-2-YL | |
MX2014002624A (es) | Nuevos derivados biciclicos de dihidroquinolina-2-ona. | |
MX2014013632A (es) | Compuestos de pirimidina para el tratamiento de cancer. | |
MX2014013074A (es) | Compuestos de n- (tetrazol-5-il) - y n- (triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas. | |
MX2021006404A (es) | Derivados de piridona policiclica sustituida y profarmaco de los mismos. | |
JO3509B1 (ar) | معدلات p2x7 | |
MX2012008141A (es) | Compuestos y metodos. | |
MY169267A (en) | New aryl-quinoline derivatives | |
MX2017000594A (es) | Derivados de bis(aril) catecol como herbicidas. | |
MX2015001099A (es) | Nuevos derivados biciclicos de piridina. | |
BR112016026046A8 (pt) | uso de compostos de tienotriazolodiazepina | |
MX343225B (es) | Nuevos derivados de aril-benzocicloalquil-amida. | |
IN2014DN07509A (es) | ||
MX2016005383A (es) | Composiciones para tratar formaciones subterraneas. | |
PH12015501038A1 (en) | Inhibitors of iap | |
MX369470B (es) | Medios y método para el tratamiento de tumores sólidos. |